Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S, COMPASS Investigators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 2019;157:agosto. [Ref.ID 103177]

Hart RG, Sharma M, Mundl H, Kasner SE, Bagdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonskowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ, NAVIGATE ESUS Investigators. Ribaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191-201. [Ref.ID 102610]

Ekelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Díaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim J-H, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Bruns NC, Misselwitz F, Chen E, Leong D, Yusuf S, for the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017:5 de octubre. [Ref.ID 102087]

Hart RG, Halperin JL. Do current guidelines result in overuse of warfarin anticoagulation in patients with atrial fibrillation?. Ann Intern Med 2009;151:355-6. [Ref.ID 86706]

Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007;147:590-1. [Ref.ID 81292]

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67. [Ref.ID 80395]

Sherman DG, Kim SG, Boop BS, Corley SD, DiMarco JP, Hart RG, Haywood LJ, Hoyte K, Kaufman ES, Kim MH, Nasco E, Waldo AL, for the National Heart Lung and Blood Institute AFFIRM Investigators. Occurrence and characteristics of stroke events in the atrial fibrillation follow-up investigation of sinus rhythm management (AFFIRM) study. Arch Intern Med 2005;165:1185-91. [Ref.ID 73963]

Hart RG. Atrial fibrillation and stroke prevention. N Engl J Med 2003;349:1015-6. [Ref.ID 67410]

Hart RG, Halperin JL, Pearce L A, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR, for the Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the stroke prevention in atrial fibrillation trials. Ann Intern Med 2003;138:831-8. [Ref.ID 66356]

van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BSP, Koefed BG, Laupacis A. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003;163:936-43. [Ref.ID 65863]

van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis. JAMA 2002;288:2441-8. [Ref.ID 64136]

Lip GYH, Ramath S, Hart RG. Antithrombotic therapy for cerebrovascular disorders. BMJ 2002;325:1161-3. [Ref.ID 64115]

Lip GYH, Hart RG, Conway DSG. Antithrombotic therapy for atrial fibrillation. BMJ 2002;325:1022-5. [Ref.ID 63935]

Hart RG, Halperin JL, McBride R, et al.. Aspirin for the primary prevention of stroke and other major vascular events. Meta-analysis and hypotheses. Arch Neurol 2000;57:326-32. [Ref.ID 53492]

Hart RG, Pearce L A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation. In response. Ann Intern Med 2000;132:841-2. [Ref.ID 51961]

Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999;131:688-95. [Ref.ID 47739]

Hart RG, Benavente O, McBride R, Pearce L A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501. [Ref.ID 47268]

Man-Son-Hing M, Laupacis A, O'Connor AM, Biggs J, Drake E, Yetisir E, Hart RG, for the Stroke Prevention in Atrial Fibrillation Investigators. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation. A randomized controlled trial. JAMA 1999;282:737-43. [Ref.ID 46644]

Hart RG. Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation. Ann Intern Med 1998;128:408. [Ref.ID 37597]

Hart RG. Anticoagulation for nonrheumatic atrial fibrillation. N Engl J Med 1997;336:441-2. [Ref.ID 30841]